Profile
| Metric | Value |
|---|---|
| Full Name | AbbVie Inc. |
| Ticker | NYSE: ABBV |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | abbvie.com |
| Employees | 55,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $220.08 | |
| Price, 1D Change | -1.81% | |
| Market Cap | $389B | |
| TTM Dividend Yield | 2.98% | |
| PE Ratio | 166.06 | |
| Beta | 0.39 | |
| Revenue | $56B | |
| Revenue, 1Y Change | +3.71% | |
| EPS | $2.39 | |
| EPS, 1Y Change | -12.08% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $1.64 | |
| Next Ex-Dividend | $1.73 | |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.39 | |
| EPS Estimate | $10.64 | |
| EPS Est. Change | +345.13% | |
| Revenue | $56.33B | |
| Revenue Estimate | $60.93B | |
| Revenue Est. Change | +8.16% | |
| Current Price | $220.08 | |
| Price Target | - | $244.00 |
| Price Tgt. Change | - | +10.87% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $11.09 | $2.72 | -75.49% | |
| $10.45 | $2.39 | -77.13% | |
| $10.64 | N/A | +345.13% | |
| $14.25 | N/A | +496.24% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $54.05B | $54.32B | +0.49% | |
| $56.04B | $56.33B | +0.52% | |
| $60.93B | N/A | +8.16% | |
| $66.69B | N/A | +18.38% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +23.29% | |
| Price, 3Y | +36.14% | |
| Market Cap, 1Y | +23.44% | |
| Market Cap, 3Y | +36.00% | |
| Revenue, 1Y | +3.71% | |
| Revenue, 3Y | +0.24% | |
| EPS, 1Y | -12.08% | |
| EPS, 3Y | -62.96% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $220.08 | |
| SMA 200 | $206.52 | |
| SMA 200 vs Price | -6.16% | |
| SMA 50 | $226.28 | |
| SMA 50 vs Price | +2.82% | |
| Beta | 0.39 | |
| ATR | $5.56 | |
| 14-Day RSI | 42.90 | |
| 10-Day Volatility | 39.15% | |
| 1-Year Volatility | 27.04% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $1.64 | |
| Upcoming | $1.73 | |
| Dividend Yield | 2.82% | |
| Total Dividend | $6.20 | |
| Dividends Paid | $11.03B | |
| Payout Ratio | 259.66% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $56.33B | |
| EPS | $2.39 | |
| Gross Profit | $39.43B | |
| Gross Margin | 69.99% | |
| Operating Profit | $9.14B | |
| Operating Margin | 16.22% | |
| Net Income | $4.25B | |
| Net Margin | 7.59% | |
| EBITDA | $9.14B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 20.40 | |
| Current Ratio | 0.66 | |
| Quick Ratio | 0.55 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 2.21 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 166.06 | |
| PS Ratio | 6.52 | |
| PB Ratio | -147.22 | |
| EV/EBITDA | 16.52 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $3.33B | |
| Cash & Equivalents | $5.56B | |
| Total Assets | $135.16B | |
| Current Assets | $25.58B | |
| Total Liabilities | $131.80B | |
| Current Liabilities | $38.75B | |
| Total Debt | $67.84B | |
| Short Term Debt | $6.80B | |
| Accounts Payable | $2.95B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $47.20B | |
| Operating Expenses | $30.29B | |
| Cost Of Goods Sold | $16.90B | |
| SG&A | $14.75B | |
| D&A | $8.39B | |
| Interest Expense | $0.00 | |
| Income Tax | -$570.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $18.81B | |
| CFI | -$20.82B | |
| CFF | -$5.21B | |
| Capex | $974.00M | |
| Free Cash Flow | $17.83B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| HSBC | → | |
| UBS | → | |
| Piper Sandler | → | |
| JP Morgan | → | |
| Citigroup | → | |
| Guggenheim | → | |
| Raymond James | → | |
| Piper Sandler | → | |
| Cantor Fitzgerald | → |
Analyst sentiment
Institutional ownership
Screeners with ABBV
Data Sources & References
- ABBV Official Website www.abbvie.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- ABBV Profile on Yahoo Finance finance.yahoo.com/quote/ABBV
- ABBV Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/abbv
FAQ
What is the ticker symbol for AbbVie Inc.?
The ticker symbol for AbbVie Inc. is NYSE:ABBV
Does AbbVie Inc. pay dividends?
Yes, AbbVie Inc. pays dividends. The last payment was $1.64, with an ex-dividend date on October 15, 2025
What sector is AbbVie Inc. in?
AbbVie Inc. is in the Healthcare sector
What industry is AbbVie Inc. in?
AbbVie Inc. is in the General Drug Manufacturers industry
What country is AbbVie Inc. based in?
AbbVie Inc. is headquartered in United States
When did AbbVie Inc. go public?
AbbVie Inc. initial public offering (IPO) was on January 2, 2013
Is AbbVie Inc. in the S&P 500?
Yes, AbbVie Inc. is included in the S&P 500 index
Is AbbVie Inc. in the NASDAQ 100?
No, AbbVie Inc. is not included in the NASDAQ 100 index
Is AbbVie Inc. in the Dow Jones?
No, AbbVie Inc. is not included in the Dow Jones index
When was AbbVie Inc. last earnings report?
AbbVie Inc.'s most recent earnings report was on October 31, 2025
When does AbbVie Inc. report earnings?
The next expected earnings date for AbbVie Inc. is February 4, 2026
